Immunotherapy Program at Northside
Northside Hospital’s Immunotherapy Program is a nationally recognized treatment center.
Northside Hospital’s Immunotherapy and CAR T-cell Program FACTS:
Within five to ten business days of the initial referral, the relapsed or refractory non-Hodgins’s lymphoma patient, acute lymphocytic leukemia, or multiple myeloma patient will be evaluated by the Northside Hospital’s immunotherapy and CAR T-cell physicians.
Dedicated cellular therapy clinical coordinators will organize and coordinate care from new patient consultation through treatment follow-up.
With onsite apheresis capabilities at Atlanta Blood Services, our team is able to schedule T-cell apheresis within days of a new patient's consultation.
Dedicated financial team that is able to expeditiously obtain financial approval for all immunotherapy treatments, including CAR T-cell.
Continuous communication with referring hematologists and oncologists to ensure bridging therapy is initiated if necessary.
Please visit immunotherapy clinical trials for a listing of leukemia, multiple myeloma, diffuse large B-cell lymphoma, and other various disease-specific immunotherapy trials.
B-CELL MALIGNANCIES
Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat B-cell malignancies:
BREYANZI®: For adult patients with:
Relapsed or refractory (R/R) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, are refractory to first-line chemoimmunotherapy, relapsed within 12 months of first-line chemoimmunotherapy, after two or more lines of systemic therapy.
Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
Relapsed or refractory (R/R) mantle cell lymphoma after two or more lines of systemic therapy, including a BTK inhibitor.
Relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), after two or more lines of systemic therapy, including a BTK inhibitor and a BCL-2 inhibitor.
KYMRIAH®: For adult patients with:
Relapsed or refractory (R/R) large B-cell lymphoma, including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, and after two or more lines of systemic therapy.
Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
TECARTUS®: For adult patients with:
Relapsed or refractory (R/R) mantle cell lymphoma (MCL)
YESCARTA®: For adult patients with:
Relapsed or refractory (R/R) large B-cell lymphoma, refractory to first-line chemoimmunotherapy, or relapse within 12 months of first-line chemoimmunotherapy.
Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
Relapsed or refractory (R/R) aggressive large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (FL), and after 2 or more line.
Available Commercial CAR T-cell Products:
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat acute lymphoblastic leukemia (ALL):
KYMRIAH®: For patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia (ALL), where ALL is refractory or in a second or later relapse.
TECARTUS®: For adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).
AUCATZYL®: For adult patients with relapsed or refractory (R/R) B-cell precursor acute lyphoblastic leukemia (ALL).
MULTIPLE MYELOMA
Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat multiple myeloma:
ABECMA®: For adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
*Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR T-cell eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939
CARVYKTI®: For adult patients with relapsed or refractory (R/R) multiple myeloma after one (1) or more prior lines of therapy, including an immunomodulatory agent and a proteasome inhibitor, who are refractory to lenalidomide.
*Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939
